the australian cannabis industry is a global global industry, and its global medical cannabis business is both defensible and stable. in this situation, we are intent on controlling what we can control and delivering on our target of reaching a profitable adjusted ebita run rate by the first half of fiscal 2023. in this situation, we are intending to achieve a positive adjusted ebita run rate by the end of the first half of fiscal 2023. we are pleased to have identified additional opportunities, and we expect they to materially reduce our cash needs. we will continue to continue to grow and provide a competitive advantage and are critical to us generating sustainable profitability. we expect to achieve a positive adjusted ebit da run rate by the end of the first half fiscal 2023.